22 February 2021 ORYZON reports results and corporate update for 4th quarter and year ended December 31, 2020
11 February 2021 ORYZON announces FDA Orphan Drug Designation granted to iadademstat for treatment of Acute Myeloid Leukemia
10 February 2021 ORYZON to present new clinical data and corporate updates at conferences in February and March
4 January 2021 ORYZON to present a corporate update and to hold multiple virtual corporate activities in January-2021
17 December 2020 ORYZON Launches Pioneering Schizophrenia Precision Medicine Study In Collaboration With Columbia Psychiatry
11 November 2020 ORYZON to present further positive efficacy data from iadademstat ALICE Phase IIa trial at the 62nd Congress of the American Society of Hematology
10 November 2020 ORYZON receives approval to start PORTICO Phase IIb trial with vafidemstat in Borderline Personality Disorder
2 November 2020 Oryzon announces appointment of Dr. Torsten Hoffmann as Global R&D Director and retirement of Dr. Tamara Maes
26 October 2020 ORYZON Reports Results for Quarter Ended September 30, 2020 and Provides Corporate Update